Alumis reports positive 52-week Phase 2 OLE data for ESK-001 in plaque psoriasis at AAD 2025

ALUMIS INC.

ESK-001 40 mg BID achieved PASI 90 61.3%, PASI 100 38.8%, sPGA 0 38.8% at Week 52 (mNRI, n=80).
Responses sustained or improved vs Week 12; 80% of ≥PASI-75 responders at Week 12 maintained or improved at Week 52.
No new safety findings; most TEAEs mild-to-moderate and self-limited.
Phase 3 ONWARD program ongoing; topline data expected Q1 2026.
Patient-reported outcomes: DLQI 0/1 61.3% and itch NRS≤4 81.3% at Week 52.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.